Home / PD-1 / Recombinant Human PD-1 Fc Chimera Protein, CF

Recombinant Human PD-1 Fc Chimera Protein, CF

Catalog #: 1086-PD
34 Citations 10 Reviews Datasheet / COA / SDS
Analyzed by SEC-MALS
Catalog # Availability Size / Price Qty
1086-PD-050
1086-PD-01M
Best Seller
Recombinant Human PD‑1 Fc Chimera Protein SEC-MALS.
2 Images
Product Details
Citations (34)
FAQs
Supplemental Products
Reviews (10)
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human PD-1 Fc Chimera Protein, CF Summary

Why choose R&D Systems PD-1 Protein, Fc Chimera?

  • Guaranteed Bioactivity and High Purity: Bioactivity tested by functional ELISA and purity determined by SDS-PAGE to be greater than 95%.
  • Lot-to-Lot Consistency: Stringent QC testing performed on each lot to ensure consistent activity and purity.
  • Bulk Quantities Available: Bulk up and save with large mass quantities to meet your research needs. Supply agreements available, partner with us. Please contact us.
  • Most Respected, Most Cited Brand in Proteins: With over 35 years of providing the best recombinant proteins to the scientific community, R&D Systems continues to lead the industry in quality, activity, and purity.

Find the non-Fc, His-tagged PD-1 protein here PD-1 Protein His

Visit Bio-Techne to explore other immune checkpoint proteins Immune Checkpoint Proteins

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. When Recombinant Human PD-1 Fc Chimera is immobilized at 0.1 µg/mL (100 µL/well), Recombinant Human B7-H1/PD-L1 Fc Chimera (Catalog # 156-B7) binds with a typical ED50 of 0.15-0.75 μg/mL.
Source
Mouse myeloma cell line, NS0-derived human PD-1 protein
Human PD-1
(Leu25-Gln167)
Accession # Q15116.3		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus
Accession #
Q15116.3
N-terminal Sequence
Analysis
Leu25
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
42.6 kDa (monomer)
SDS-PAGE
60 - 70 kDa, under reducing conditions.

Product Datasheets

You must select a language.

x

1086-PD

Product Datasheet
COA
SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

1086-PD

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

SEC-MALS View Larger

Recombinant human PD-1/Fc (Catalog # 1086-PD) has a molecular weight (MW) of 125.1 kDa as analyzed by SEC-MALS, suggesting that this protein is a homodimer.  MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).

Bioactivity Graph showing bioactivity of Human PD-1 protein View Larger

When Recombinant Human PD-1 Fc Chimera (Catalog # 1086-PD) is coated at 0.1 µg/mL, Recombinant Human B7-H1/PD-L1 Fc Chimera (156-B7) binds with a typical ED50 of 0.15-0.75 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: PD-1

PD-1 (Programmed Death-1 receptor), also known as CD279, is a receptor expressed on T cells responsible for modulating T cell activation. Like CTLA‑4, PD-1 is classified as an immune checkpoint inhibitory receptor. When PD-1 protein binds to PD-L1, it initiates a negative signaling cascade inhibiting activation of T cells. The cytoplasmic tail contains two tyrosine residues that form the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important for mediating PD-1 signaling. Normally, PD-1 helps keep T cells from attacking other cells in the body. However, many cancers take advantage of this by expressing high amounts of PD-L1 allowing cancer cells to evade the body's own immune response. Blocking the PD-1:PD-L1 interaction has proven successful in treating many different cancer types.

PD-1 protein is type I transmembrane receptor belonging to the CD28 family of immune regulatory receptors (1). Other members of this family include CD28, CTLA‑4, ICOS, and BTLA (2-5). Mature human PD-1 consists of an extracellular region (ECD) with one immunoglobulin-like V‑type domain, a transmembrane domain, and a cytoplasmic region. The mature ECD of human PD-1 shares 61% amino acid sequence identity with mouse PD-1 ECD. PD-1 protein acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (6, 7). PD‑1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and also on nonhematopoietic cells such as lung endothelial cells and hepatocytes (8, 9). Ligation of PD-L1 with PD-1 induces co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion (10). Thus, the PD-1:PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance (11).

References
  1. Ishida, Y. et al. (1992) EMBO J. 11:3887.
  2. Sharpe, A.H. and G.J. Freeman (2002) Nat. Rev. Immunol. 2:116.
  3. Coyle, A. and J. Gutierrez-Ramos (2001) Nat. Immunol. 2:203.
  4. Nishimura, H. and T. Honjo (2001) Trends Immunol. 22:265.
  5. Watanabe, N. et al. (2003) Nat. Immunol. 4:670.
  6. Zhang, X. et al. (2004) Immunity 20:337.
  7. Lázár-Molnár, E. et al. (2008) Proc. Natl. Acad. Sci. USA 105:10483.
  8. Nishimura, H. et al. (1996) Int. Immunol. 8:773.
  9. Keir, M.E. et al. (2008) Annu. Rev. Immunol. 26:677.
  10. Butte, M.J. et al. (2007) Immunity 27:111.
  11. Okazaki, T. et al. (2013) Nat. Immunol. 14:1212.
  12. Iwai, Y. et al. (2002) Proc. Natl. Acad. Sci. USA 99:12293.
  13. Nogrady, B. (2014) Nature 513:S10.
Long Name
Programmed Death-1
Entrez Gene IDs
5133 (Human); 18566 (Mouse); 301626 (Rat); 100533201 (Porcine); 486213 (Canine); 102123659 (Cynomolgus Monkey)
Alternate Names
CD279 antigen; CD279; hPD-1; PD1; PD-1; PD1hPD-l; PDCD1; programmed cell death 1; programmed cell death protein 1; Protein PD-1; SLEB2

Citations for Recombinant Human PD-1 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

34 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies
    Authors: Manna, L;Rapuano Lembo, R;Yoshioka, A;Nakamura, K;Passariello, M;De Lorenzo, C;
    Cancers
    Species: Human
    Sample Types: Antibody
    Applications: Bioassay
  2. Clinical Staphylococcus aureus inhibits human T-cell activity through interaction with the PD-1 receptor
    Authors: Mellergaard, M;Skovbakke, SL;Jepsen, SD;Panagiotopoulou, N;Hansen, ABR;Tian, W;Lund, A;Høgh, RI;Møller, SH;Guérillot, R;Hayes, AS;Erikstrup, LT;Andresen, L;Peleg, AY;Larsen, AR;Stinear, TP;Handberg, A;Erikstrup, C;Howden, BP;Goletz, S;Frees, D;Skov, S;
    mBio
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry Control
  3. The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
    Authors: Erlichman, N;Meshel, T;Baram, T;Abu Raiya, A;Horvitz, T;Ben-Yaakov, H;Ben-Baruch, A;
    Cells
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Influence on Soluble and Membrane Bound ICOS in Combination with Immune Checkpoint Blockade
    Authors: Li, X;Li, J;Zheng, Y;Lee, SJ;Zhou, J;Giobbie-Hurder, A;Butterfield, LH;Dranoff, G;Hodi, FS;
    Cancer immunology research
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  5. Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development
    Authors: T Phakham, C Boonkrai, T Wongtangpr, T Audomsun, C Attakitban, P Saelao, P Muanwien, S Sooksai, N Hirankarn, T Pisitkun
    Scientific Reports, 2022-10-22;12(1):17792.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  6. Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs
    Authors: Q Wang, Y Cao, L Shen, T Xiao, R Cao, S Wei, M Tang, L Du, H Wu, B Wu, Y Yu, S Wang, M Wen, B OuYang
    Science Advances, 2022-08-26;8(34):eabq4722.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy
    Authors: SS Ghaderi, F Riazi-Rad, ES Qamsari, S Bagheri, F Rahimi-Jam, Z Sharifzade
    BMC biotechnology, 2022-08-23;22(1):22.
    Species: Human
    Sample Types: Phage
    Applications: Bioassay
  8. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
    Authors: R Zhang, Y Yang, W Dong, M Lin, J He, X Zhang, T Tian, Y Yang, K Chen, QY Lei, S Zhang, Y Xu, L Lv
    Proceedings of the National Academy of Sciences of the United States of America, 2022-02-22;119(8):.
    Species: Human
    Sample Types: Recombinant Proteins
    Applications: Bioassay
  9. Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes
    Authors: N Erlichman, T Baram, T Meshel, D Morein, B Da'adoosh, A Ben-Baruch
    Cancers, 2022-02-18;14(4):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
    Authors: CJ Edwards, A Sette, C Cox, B Di Fiore, C Wyre, D Sydoruk, D Yadin, P Hayes, S Stelter, PD Bartlett, M Zuazo, MJ Garcia-Gra, G Benedetti, S Fiaska, NR Birkett, Y Teng, C Enever, H Arasanz, A Bocanegra, L Chocarro, G Fernandez, R Vera, B Archer, I Osuch, M Lewandowsk, YM Surani, G Kochan, D Escors, J Legg, AJ Pierce
    British Journal of Cancer, 2021-12-30;0(0):.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay
  11. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity
    Authors: Y Ren, Y Qian, L Ai, Y Xie, Y Gao, Z Zhuang, J Chen, YX Chen, JY Fang
    Nature Communications, 2021-09-13;12(1):5405.
    Species: Human
    Sample Types: Whole Cells
    Applications: Binding Assay
  12. Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
    Authors: C Vetrei, M Passariell, G Froechlich, R Rapuano Le, N Zambrano, C De Lorenzo
    Cancers, 2021-06-08;13(12):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
    Authors: JJ Park, EP Thi, VH Carpio, Y Bi, AG Cole, BD Dorsey, K Fan, T Harasym, CL Iott, S Kadhim, JH Kim, ACH Lee, D Nguyen, BS Paratala, R Qiu, A White, D Lakshminar, C Leo, RK Suto, R Rijnbrand, S Tang, MJ Sofia, CB Moore
    Nature Communications, 2021-02-22;12(1):1222.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1
    Authors: D Zhu, R Xu, X Huang, Z Tang, Y Tian, J Zhang, X Zheng
    Cell Death and Differentiation, 2020-12-16;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  15. Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity
    Authors: C Li, H Yao, H Wang, JY Fang, J Xu
    Oncogene, 2020-12-15;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  16. Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity
    Authors: N Silva-Pili, E Martisova, MC Ballestero, S Hervas-Stu, N Casares, G González-S, C Smerdou, L Vanrell
    Biomedicines, 2020-12-02;8(12):.
    Species: Human
    Sample Types: Cell Culture Supernates, Recombinant Protein
    Applications: Bioassay, ELISA Capture
  17. MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis
    Authors: M Liberelle, R Magnez, X Thuru, Y Bencheikh, S Ravez, C Quenon, AS Drucbert, C Foulon, P Melnyk, IV Seuningen, N Lebègue
    Sci Rep, 2019-11-13;9(1):16678.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
    Authors: M Passariell, AM D'Alise, A Esposito, C Vetrei, G Froechlich, E Scarselli, A Nicosia, C De Lorenzo
    Sci Rep, 2019-09-11;9(1):13125.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  19. Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-kB contributes to UV radiation-induced immune suppression
    Authors: W Wang, NM Chapman, B Zhang, M Li, M Fan, RN Laribee, MR Zaidi, LM Pfeffer, H Chi, ZH Wu
    Cancer Res., 2019-02-08;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  20. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1
    Authors: N Zhang, Y Dou, L Liu, X Zhang, X Liu, Q Zeng, Y Liu, M Yin, X Liu, H Deng, D Song
    EBioMedicine, 2019-01-31;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  21. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity
    Authors: H Wang, H Yao, C Li, H Shi, J Lan, Z Li, Y Zhang, L Liang, JY Fang, J Xu
    Nat. Chem. Biol., 2018-11-05;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry, ICC
  22. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients
    Authors: A Osa, T Uenami, S Koyama, K Fujimoto, D Okuzaki, T Takimoto, H Hirata, Y Yano, S Yokota, Y Kinehara, Y Naito, T Otsuka, M Kanazu, M Kuroyama, M Hamaguchi, T Koba, Y Futami, M Ishijima, Y Suga, Y Akazawa, H Machiyama, K Iwahori, H Takamatsu, I Nagatomo, Y Takeda, H Kida, EA Akbay, PS Hammerman, KK Wong, G Dranoff, M Mori, T Kijima, A Kumanogoh
    JCI Insight, 2018-10-04;3(19):.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA (Capture)
  23. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer
    Authors: B Shao, CW Li, SO Lim, L Sun, YJ Lai, J Hou, C Liu, CW Chang, Y Qiu, JM Hsu, LC Chan, Z Zha, H Li, MC Hung
    Am J Cancer Res, 2018-09-01;8(9):1837-1846.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  24. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
    Authors: CW Li, SO Lim, EM Chung, YS Kim, AH Park, J Yao, JH Cha, W Xia, LC Chan, T Kim, SS Chang, HH Lee, CK Chou, YL Liu, HC Yeh, EP Perillo, AK Dunn, CW Kuo, KH Khoo, JL Hsu, Y Wu, JM Hsu, H Yamaguchi, TH Huang, AA Sahin, GN Hortobagyi, SS Yoo, MC Hung
    Cancer Cell, 2018-02-12;33(2):187-201.e10.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  25. Rapid PD-L1 detection in tumors with PET using a highly specific peptide
    Authors: Samit Chatterjee
    Biochem. Biophys. Res. Commun, 2016-12-24;0(0):.
    Applications: Bioassay
  26. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
    Nat Commun, 2016-08-30;7(0):12632.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  27. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers
    Nature, 2016-05-23;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  28. B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor.
    Authors: Yang Y, Wu K, Zhao E, Li W, Shi L, Xie G, Jiang B, Wang Y, Li R, Zhang P, Shuai X, Wang G, Tao K
    Oncol Lett, 2015-02-10;9(4):1833-1838.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  29. Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.
    Authors: Melendreras S, Martinez-Camblor P, Menendez A, Bravo-Mendoza C, Gonzalez-Vidal A, Coto E, Diaz-Corte C, Ruiz-Ortega M, Lopez-Larrea C, Suarez-Alvarez B
    PLoS ONE, 2014-12-05;9(12):e113396.
    Species: Human
    Sample Types: Serum
    Applications: ELISA (Standard)
  30. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
    Authors: Steidl C, Shah SP, Woolcock BW
    Nature, 2011-03-02;471(7338):377-81.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  31. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
    Authors: Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W, Stankevich E, Pons A, Salay T, McMiller T, Gilson M, Wang C, Selby M, Taube J, Anders R, Chen L, Korman A, Pardoll D, Lowy I, Topalian S
    J Clin Oncol, 2010-06-01;28(19):3167-75.
    Species: Human
    Sample Types: Serum
    Applications: ELISA (Capture)
  32. Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression.
    Authors: Kim YS, Park GB, Lee HK, Song H, Choi IH, Lee WJ, Hur DY
    J. Immunol., 2008-11-01;181(9):6158-69.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  33. Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis.
    Authors: Sakthivel P, Ramanujam R, Wang XB, Pirskanen R, Lefvert AK
    J. Neuroimmunol., 2007-11-26;193(1):149-55.
    Applications: ELISA (Standard)
  34. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis.
    Authors: Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ
    J. Immunol., 2006-12-15;177(12):8844-50.
    Species: Human
    Sample Types: N/A, Whole Cells
    Applications: Bioassay, ELISA (Standard)

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human PD-1 Fc Chimera Protein, CF

Average Rating: 4.7 (Based on 10 Reviews)

5 Star
80%
4 Star
10%
3 Star
10%
2 Star
0%
1 Star
0%

Have you used Recombinant Human PD-1 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 07/13/2024
Application: Cell migration/motility
Cell migration/motility Recombinant Human PD-1 Fc Chimera Protein, CF 1086-PD
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 06/26/2020
Application: In vitro bioactivity in cell culture
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 01/15/2020
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 01/12/2020
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 11/22/2019
Application: Binding assay/Protein-protein interaction

Cells expressing a negative control (left) or hPD-L1 mCherry (right) were treated with 0.25 ug of hPD-1 hIgG1. Cells were analyzed by flow cytometry with binding detected using an anti-human 488 secondary antibody.

Binding assay/Protein-protein interaction Recombinant Human PD-1 Fc Chimera Protein, CF 1086-PD
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 08/20/2018
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 12/08/2017
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-1 Fc Chimera Protein, CF
By Jenna Nguyen on 11/03/2017
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-1 Fc Chimera Protein, CF
By Sam Mullapudi on 04/21/2017
Recombinant Human PD-1 Fc Chimera Protein, CF
By Songbo Qiu on 07/08/2016
Application: Binding assay/Protein-protein interaction

Sorry that I just rate the catalog based on my alike recombinant PD1 peptide. I have one question for the peptide. Owing the Ig like peptide with Fc fragment. So when we detect it binding to PDL1 on cell assay, it is difficult to get definite conclusion if it is PDL1 binding or others.
My protocol is as below:
-Cells with PDL1 high level was treated by PD1 like peptide,
-4degree 1hr
-collected and lysis
-WB by anti-IgG to Fc recognization.
Result: weak signal. you don't know if it is non-specific binding

***Bio-Techne Response: Thank you for reviewing our product. We are sorry to hear that this antibody did not perform as expected. We have been in touch with the customer to resolve this issue according to our Product Guarantee and to the customer’s satisfaction.***